HK1113374A1 - Immunotherapeutic formulations with interleukin-2-neutralising capacity - Google Patents

Immunotherapeutic formulations with interleukin-2-neutralising capacity

Info

Publication number
HK1113374A1
HK1113374A1 HK08102535.0A HK08102535A HK1113374A1 HK 1113374 A1 HK1113374 A1 HK 1113374A1 HK 08102535 A HK08102535 A HK 08102535A HK 1113374 A1 HK1113374 A1 HK 1113374A1
Authority
HK
Hong Kong
Prior art keywords
interleukin
neutralising capacity
immunotherapeutic formulations
immunotherapeutic
formulations
Prior art date
Application number
HK08102535.0A
Other languages
English (en)
Inventor
Jose Enrique Montero Casimiro
Livan Bladimir Alonso Sarduy
Rolando Perez Rodriguez
Agustin Bienvenido Lage Davila
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of HK1113374A1 publication Critical patent/HK1113374A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK08102535.0A 2004-11-16 2008-03-05 Immunotherapeutic formulations with interleukin-2-neutralising capacity HK1113374A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20040261A CU23297A1 (es) 2004-11-16 2004-11-16 Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
PCT/CU2005/000009 WO2006053508A1 (es) 2004-11-16 2005-11-16 Formulaciones inmunoterapeuticas con capacidad neutralizante de la interleucina-2.

Publications (1)

Publication Number Publication Date
HK1113374A1 true HK1113374A1 (en) 2008-10-03

Family

ID=40122436

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08102535.0A HK1113374A1 (en) 2004-11-16 2008-03-05 Immunotherapeutic formulations with interleukin-2-neutralising capacity

Country Status (25)

Country Link
US (1) US20090274647A1 (xx)
EP (2) EP2112160B1 (xx)
JP (1) JP5227028B2 (xx)
KR (1) KR101240457B1 (xx)
CN (1) CN101061136B (xx)
AR (1) AR051494A1 (xx)
AT (1) ATE525393T1 (xx)
AU (1) AU2005306186B2 (xx)
BR (1) BRPI0518007A (xx)
CA (1) CA2588573C (xx)
CR (1) CR9097A (xx)
CU (1) CU23297A1 (xx)
EA (1) EA012072B1 (xx)
GE (1) GEP20105039B (xx)
HK (1) HK1113374A1 (xx)
MA (1) MA29044B1 (xx)
MX (1) MX2007005808A (xx)
MY (1) MY162106A (xx)
PE (1) PE20061172A1 (xx)
SG (1) SG122897A1 (xx)
TN (1) TNSN07187A1 (xx)
TR (1) TR200704213T2 (xx)
TW (1) TWI433853B (xx)
WO (1) WO2006053508A1 (xx)
ZA (1) ZA200703528B (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009542592A (ja) * 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法
US10114018B2 (en) 2014-04-22 2018-10-30 INSERM (Institut National de la Santé et de la Recherche Médicale) IL-2 peptide derivatives, and uses thereof for the diagnosis and treatment of an autoimmune disease
TW201722989A (zh) * 2015-10-23 2017-07-01 輝瑞大藥廠 抗il-2抗體及其組合物及用途
CU20210021A7 (es) * 2021-03-30 2022-11-07 Ct Inmunologia Molecular Composicones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5939832A (ja) * 1982-08-28 1984-03-05 Ajinomoto Co Inc モノクロ−ナル抗体ならびにその製法、使用法
EP0111344A2 (en) * 1982-12-13 1984-06-20 Sloan-Kettering Institute For Cancer Research Anti-interleukin-2 monoclonal antibodies
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US5643565A (en) * 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
WO1991001146A1 (en) * 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
JPH10147952A (ja) 1996-11-18 1998-06-02 Komatsu Ltd ブルドーザのドージング装置
US20040156824A1 (en) * 1996-12-23 2004-08-12 Epstein Alan L. Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
CA2219961C (en) * 1998-01-09 2010-06-01 The University Of Southern California Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
US6168785B1 (en) * 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
PL200919B1 (pl) * 1999-02-12 2009-02-27 Lexigen Pharm Corp Zastosowanie kompozycji czynnika hamującego angiogenezę i czynnika przeciwnowotworowego, kompozycja terapeutyczna do leczenia nowotworów i zestaw do traktowania komórki nowotworowej
AU2001259253A1 (en) * 2000-04-26 2001-11-07 National Jewish Medical And Research Center Product and process for regulation of t cell responses
CU23011A1 (es) * 2000-11-03 2004-12-17 Ct Ingenieria Genetica Biotech Método de obtención de estructuras antigénicas quemétodo de obtención de estructuras antigénicas que potencian la reactividad cruzada específica y su potencian la reactividad cruzada específica y su uso en formulaciones uso en formulaciones
CU23077A1 (es) * 2000-12-06 2005-08-17 Centro Inmunologia Molecular Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
CU22979A1 (es) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
CU22999A1 (es) * 2001-12-04 2004-10-12 Centro Inmunologia Molecular Método de tratamiento de enfermedades malignas e infecciosas crónicas
WO2002087304A2 (de) * 2001-04-30 2002-11-07 Frohnhofen, Wilfried Il2-peptide; von interleukin 2 abgeleitete peptide und peptid-dimere
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
ITMI20012527A1 (it) 2001-11-30 2003-05-30 Unihart Corp Proteine di fusione contenenti peptidi tlp
JP4364643B2 (ja) * 2001-11-30 2009-11-18 アメリカ合衆国 前立腺特異抗原のペプチドアゴニストおよびその使用
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
US7569215B2 (en) * 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides

Also Published As

Publication number Publication date
EP2112160A3 (en) 2010-01-13
EA012072B1 (ru) 2009-08-28
EP2112160A2 (en) 2009-10-28
CR9097A (es) 2007-08-28
MX2007005808A (es) 2007-07-20
EP1829893B1 (en) 2011-09-21
CA2588573C (en) 2013-12-31
PE20061172A1 (es) 2006-12-16
EP1829893A1 (en) 2007-09-05
JP2008526686A (ja) 2008-07-24
JP5227028B2 (ja) 2013-07-03
CN101061136A (zh) 2007-10-24
EA200701071A1 (ru) 2007-12-28
ATE525393T1 (de) 2011-10-15
TNSN07187A1 (en) 2008-11-21
TR200704213T2 (tr) 2007-08-21
CA2588573A1 (en) 2006-05-26
EP2112160B1 (en) 2015-07-08
MY162106A (en) 2017-05-31
KR20070084025A (ko) 2007-08-24
AR051494A1 (es) 2007-01-17
TW200631591A (en) 2006-09-16
BRPI0518007A (pt) 2008-10-21
ZA200703528B (en) 2008-06-25
GEP20105039B (en) 2010-07-12
WO2006053508A1 (es) 2006-05-26
CN101061136B (zh) 2012-12-05
KR101240457B1 (ko) 2013-03-08
CU23297A1 (es) 2008-07-24
MA29044B1 (fr) 2007-11-01
TWI433853B (zh) 2014-04-11
AU2005306186A1 (en) 2006-05-26
US20090274647A1 (en) 2009-11-05
SG122897A1 (en) 2006-06-29
AU2005306186B2 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
TWI319908B (en) Storage element
EP1810116A4 (en) DIGITAL STORAGE UNIT WITH AUTOMATIC LABELING
EP1737564A4 (en) META-MECHANICAL MATERIALS
EP1790612A4 (en) NANOCAPSULE TYPE STRUCTURE
IL178884A0 (en) Novel cis-imidazolines
AU304569S (en) Lipstick case
ZA200701433B (en) Selection
GB0415789D0 (en) Novel combination
GB0406563D0 (en) Improved parasol
HK1113374A1 (en) Immunotherapeutic formulations with interleukin-2-neutralising capacity
GB0425658D0 (en) Immunotherapeutic agent
EP1728725A4 (en) STORAGE CONTAINERS
GB0427131D0 (en) Novel combination
GB2412063B (en) Umbrella structure
GB0421668D0 (en) Storage units
GB0408865D0 (en) Novel benzoxazocines
GB0427245D0 (en) Novel formulations
GB0427244D0 (en) Novel formulations
GB0426292D0 (en) Novel formulations
GB0420821D0 (en) Novel formulations
GB0427249D0 (en) Novel formulations
GB0420820D0 (en) Novel formulations
GB0427247D0 (en) Novel formulations
GB0427248D0 (en) Novel formulations
GB0420818D0 (en) Novel formulations

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20161116